Erratum to “Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D, Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment” Kidney Int. 2020;97:1287–1296

The publisher regrets that the members of the 311 Study Group were not included as collaborative authors. Members of the 311 Study Group are listed in the Appendix. The publisher would like to apologize for any inconvenience caused. Sunil Babu (Principle Investigator [PI]), Fort Wayne Medical Oncology and Hematology, Fort Wayne, IN, USA; Nilufer Broeders (PI) and Nicole Lietar, Université libre de Bruxelles – Erasme, Brussels, Belgium; Fiona Brown (PI), Monash Medical Centre, Clayton, Victoria, Australia; Philip Campbell (PI), Barwon Health, University Hospital Geelong, Geelong, Victoria, Australia; Paramit Chowdhury (PI) and Theo Kasimatis, Guy’s Hospital, Guy’s and St Thomas’ NHS Foundation Trust, London, UK; Lino Cirami (PI), Leonardo Caroti, and Guilia Antognoli, Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy; Yahsou Delmas (PI), Hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France; Vladimir Dobronravov (PI), FSBEI HE I.P. Pavlov SPbSMU MOH, St. Petersburg, Russia; Anja Gaeckler (PI), Universitaetsklinikum Essen, Essen, Germany; Cyril Garrouste (PI), Clermont-Ferrand Hôpital, CHU Gabriel-Montpied, Clermont-Ferrand, France; Gregory Greenwood (PI), Novant Health Forsyth Medical Center, Winston-Salem, NC, USA; Siân Griffin (PI), University Hospital of Wales, Wales, UK; Chiu-Ching Huang (PI) and I-Ru Chen, China Medical University Hospital, Taichung City, Taiwan; Susan Huang (PI), London Health Sciences Center, London, Ontario, Canada; Jin Seok Kim (PI), Severance Hospital, Yonsei University Health System, Seoul, Republic of Korea; Gaetano La Manna (PI), Giorgia Comai, and Maria Cappuccilli, Azienda Ospedaliera Universitaria Policlinico Sant’Orsola Malpighi, Bologna, Italy; Moglie Le Quintrec (PI) and Guillaume Jeantet, Hopital Lapeyronie, CHU De Montpellier, Montpellier, France; Iino Fumie, Saitama Medical University, Iruma, Japan; Yosu Luque, Hôpitaux de Paris 6, Sorbonne Université, Paris, France; Jan Menne, Hannover Medical School, Hannover, Germany; Johan Morelle (PI) and Eric Goffin, Cliniques Universitaires Saint-Luc, Brussels, Belgium; Anja Muhlfeld (PI), Universitaetsklinikum Aachen, AöR, Medizinische Klinik II, Aachen, Germany; Shashi Nagaraj (PI) and Gowthami Arepally, Duke University, Durham, NC, USA; Doyeun Oh (PI), CHA Bundang Medical Center, CHA University, Seongnam, Gyeonggi-do, Republic of Korea; Masayoshi Okumi (PI), Tokyo Women’s Medical University Hospital, Tokyo, Japan; Manuel Praga Terente (PI), Elena Gutierréz, and Paola Rodriguez, Hospital Universitario 12 de Octubre, Madrid, Spain; Francois Provot (PI), Hôpital Claude Huriez, Chu de Lille, Lille, France; Ulf Schönermarck (PI) and Michael Fischereder, Medizinische Klinik IV, Klinikum der Universität, LMU, Munich, Germany; Natalia Ramos Terrada, University Hospital Vall d’Hebron, Barcelona, Spain; Barbara Seitz-Polski (PI), Guillaume Favre, and Sonia Boyer-Suavet, Hôpital Pasteur, CHU de Nice, Nice, France; Maria Vinogradova (PI) and Tatiana Kirsanova, FSBI of the Ministry of Healthcare of Russia, Moscow, Russia; and Edwin K.S. Wong, Royal Victoria Hospital, Newcastle University, Newcastle upon Tyne, UK The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatmentKidney InternationalVol. 97Issue 6PreviewRavulizumab is a long-acting C5 inhibitor engineered from eculizumab with increased elimination half-life, allowing an extended dosing interval from two to eight weeks. Here we evaluate the efficacy and safety of ravulizumab in adults with atypical hemolytic uremic syndrome presenting with thrombotic microangiopathy. In this global, phase 3, single arm study in complement inhibitor-naïve adults (18 years and older) who fulfilled diagnostic criteria for atypical hemolytic uremic syndrome, enrolled patients received ravulizumab through a 26-week initial evaluation period. Full-Text PDF Open Access